Stem cell therapy is being used in every area of clinical medicine. The general area of autoimmune disorders is one of the most promising. While the tissue regenerative aspects of stem cell therapy garner the most attention, their immune-modulatory capabilities are at least as important. For reasons that are only partially clear, diabetes is becoming increasingly common. It requires strict long term care to minimize its effects including frequent insulin injections and often insulin pumps. These are time consuming, expensive, and limiting to patients. And they do no completely control its long term effects. Diabetes is a leading cause of both blindness and kidney disease for example. There are many areas of ongoing stem cell research to treat Diabetes. However a 2013 paper entitled "Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial" by Yong Zhao et al. showed remarkable results from a brilliant and completely different use of stem cell therapy than any prior studies.